LEO Pharma's delgocitinib cream has launched in Germany, for those suffering chronic hand eczma (CHE), with the European country becoming the first to make the topical cream available.
Phase 3 trials, delta 1 and delta 2, showed significant clinical improvements for delgocitinib users, supporting the cream's efficacy, and seeing it receive European Commission approval.
"Whilst CHE as a disease has a high unmet need and has long been overlooked internationally when it comes to medical research, here in the German population, the hand eczema prevalence is high and CHE is a real problem for the patients," LEO Medical Director Urs Kerkmann said.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Oct 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Oct 24
